Morpheus® II HT-96 MD1-92
Morpheus II - 96 x 1mL conditions optimized to yield crystals not observed in
traditional screens and also includes heavy atoms for experimental
phasing as well as polyols for cryoprotection.
Features of Morpheus® II HT-96 (MD1-92):
- Targeted incorporation of 35 low- molecular weight PDB ligands into 96 conditions.
- Incorporation of heavy atoms as additives for experimental phasing.
- Suitable for membrane proteins with PEGS and polyols as main precipitants.
- The inclusion of NDSBs, polyamines, amino acids and monosaccharides to enhance solubility and stability of many proteins for crystallization.
- New polyols included for cryoprotection of conditions: no need to investigate more conditions for cryo-cooling.
- Innovative buffer systems facilitate pH optimization.
- Readily available Morpheus® II Optimization reagents including the Mixes and Stock reagents.
Morpheus® II follows the general design principles of the original Morpheus screen, but less typical additives have been included, such as heavy metals, NDSBs, polyamines, amino acids and monosaccharides. In addition, various polyols have been added for cryoprotection along with innovative buffer systems.
Some additives such as metal divalent cations can induce new crystal contacts. Heavy atoms were integrated to help with ab initio structure determination since a common issue to solve novel structure is the phase problem. Most of the other additives are meant to alter protein stability and solubility (carboxylic acids, polyamines and monosaccharides).
- Gorrec, F (2009), The MORPHEUS protein crystallization screen J Appl Cryst 42, 1035-1042
- Gorrec, F (2013), The current approach to initial crystallization screening of proteins is under-sampled J Appl Cryst 46, 795-797.
- Gorrec, F (2015), The Morpheus II protein crystallization screen, ICCBM15 proceedings (Special Issue Acta Cryst F71, p. 831-837).